Междисциплинарное общество специалистов по опухолям печени (МОСОП)
⚠️Дисклеймер⚠️ Материалы, публикуемые в данной группе, предназначены исключительно для сотрудников здравоохрпнения. Сообщество не несет ответственность за любые последствия в случае прочтения данного текста человеком без высшего медицинского образования.
Show more- Subscribers
- Post coverage
- ER - engagement ratio
Data loading in progress...
Data loading in progress...
The FDA has granted orphan drug designation to the novel oncolytic virotherapy CF33-hNIS for cholangiocarcinoma.
Автор: Воронкова Наталья Васильевна, к.м.н., инфекционист, Университетская клиника Н-Clinic В инфекционной гепатологии HBV-инфекция до сих пор остается некоторой «вещью в себе» с точки зрения понимания закономерностей течения, оптимального мониторинга, эффективного лечения и адекватного прогноза. И сопряжено это, несомненно, с особенностями самого вируса гепатита В и его жизненного цикла. Поэтому прежде, чем говорить о специфических маркерах HBV-инфекции, давайте кратко вспомним особенности строения вируса…
This study investigated the efficacy and safety of radiotherapy combined with targeted therapy and immunotherapy in treating hepatocellular carcinoma and p
PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTS In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected…
The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.
This randomized clinical trial assesses the effect of tranexamic acid vs placebo on the need for blood transfusion among patients undergoing cancer-related liver resection.
Your current plan allows analytics for only 5 channels. To get more, please choose a different plan.